Talaris Therapeutics, Inc. (TALS)

$1.45

+0.11 (+8.21%)
Rating:
Recommendation:
-
Symbol TALS
Price $1.45
Beta 0.000
Volume Avg. 0.21M
Market Cap 60.149M
Shares () -
52 Week Range 0.89-10.56
1y Target Est -
DCF Unlevered TALS DCF ->
DCF Levered TALS LDCF ->
ROE -31.84% Strong Sell
ROA -33.70% Strong Sell
Operating Margin -
Debt / Equity 5.99% Neutral
P/E -
P/B 0.31 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest TALS news


Healthcare
Biotechnology
NASDAQ Global Market

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.